Yuval A Patel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4484376/publications.pdf

Version: 2024-02-01

47 628 12 23
papers citations h-index g-index

48 48 48 1002 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Liver transplantation for hepatocellular carcinoma: Management after the transplant. American Journal of Transplantation, 2020, 20, 333-347.	4.7	88
2	Racial and Socioeconomic Disparities in Utilization of Telehealth in Patients with Liver Disease During COVID-19. Digestive Diseases and Sciences, 2022, 67, 93-99.	2.3	78
3	Algorithm for the management of ERCP-related perforations. Gastrointestinal Endoscopy, 2016, 83, 934-943.	1.0	55
4	Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation. Digestive Diseases and Sciences, 2016, 61, 1406-1416.	2.3	53
5	Textbook Outcomes in Liver Transplantation. World Journal of Surgery, 2020, 44, 3470-3477.	1.6	40
6	Risk factors for biopsyâ€proven advanced nonâ€alcoholic fatty liver disease in the Veterans Health Administration. Alimentary Pharmacology and Therapeutics, 2018, 47, 268-278.	3.7	33
7	Outcomes of liver retransplantation in patients with primary sclerosing cholangitis. Liver Transplantation, 2017, 23, 769-780.	2.4	26
8	Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration. Digestive Diseases and Sciences, 2018, 63, 2259-2266.	2.3	26
9	The Impact of the 2017 Kidney Allocation Policy Change on Simultaneous Liverâ€Kidney Utilization and Outcomes. Liver Transplantation, 2021, 27, 1106-1115.	2.4	21
10	Outcomes of Liver Transplantation Among Older Recipients With Nonalcoholic Steatohepatitis in a Large Multicenter US Cohort: the Reâ€Evaluating Age Limits in Transplantation Consortium. Liver Transplantation, 2020, 26, 1492-1503.	2.4	20
11	Use of Skeletal Muscle Index as a Predictor of Waitâ€List Mortality in Patients With Endâ€Stage Liver Disease. Liver Transplantation, 2020, 26, 1090-1099.	2.4	18
12	Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. Clinical Gastroenterology and Hepatology, 2022, 20, 183-193.	4.4	15
13	Renal Outcomes After Simultaneous Liverâ€Kidney Transplantation: Results from the US Multicenter Simultaneous Liverâ€Kidney Transplantation Consortium. Liver Transplantation, 2021, 27, 1144-1153.	2.4	13
14	Predictors of Post-Operative Pain Relief in Patients with Chronic Pancreatitis Undergoing the Frey or Whipple Procedure. Journal of Gastrointestinal Surgery, 2016, 20, 734-740.	1.7	12
15	Transplant Outcomes in Older Patients With Nonalcoholic Steatohepatitis Compared to Alcohol-related Liver Disease and Hepatitis C. Transplantation, 2020, 104, e164-e173.	1.0	11
16	Health Equity and Telemedicine in Gastroenterology and Hepatology. Clinical Gastroenterology and Hepatology, 2021, 19, 1516-1519.	4.4	11
17	Evaluation of New-Onset Ascites. JAMA - Journal of the American Medical Association, 2016, 316, 340.	7.4	10
18	Differences in Phenotypes and Liver Transplantation Outcomes by Age Group in Patients with Primary Sclerosing Cholangitis. Digestive Diseases and Sciences, 2017, 62, 3200-3209.	2.3	10

#	Article	IF	CITATIONS
19	Trends in statin utilisation in US adults with nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2021, 54, 1481-1489.	3.7	10
20	Pancreatic metastasis from a solitary fibrous tumor of the kidney: A rare cause ofÂacute recurrent pancreatitis. Pancreatology, 2013, 13, 631-633.	1.1	9
21	Aging of the Liver: What This Means for Patients with HIV. Current HIV/AIDS Reports, 2016, 13, 309-317.	3.1	8
22	Impact of Covid-19 on kidney transplant and waiting list patients: Lessons from the first wave of the pandemic. Nephrologie Et Therapeutique, 2021, 17, 245-251.	0.5	8
23	Temporal Trends and Evolving Outcomes After Simultaneous Liverâ€kidney Transplantation: Results from the US SLKT Consortium. Liver Transplantation, 2021, 27, 1613-1622.	2.4	7
24	The impact of human leukocyte antigen donor and recipient serotyping and matching on liver transplant graft failure in primary sclerosing cholangitis, autoimmune hepatitis, and primary biliary cholangitis. Clinical Transplantation, 2018, 32, e13388.	1.6	6
25	Telemedicine in Hepatology: Current Applications and Future Directions. Liver Transplantation, 2022, 28, 294-303.	2.4	6
26	Access to technology to support telehealth in areas without specialty care for liver disease. Hepatology, 2023, 77, 176-185.	7.3	5
27	Decreasing Endoscopy No-Shows Using a Lean Improvement Framework. Clinical Gastroenterology and Hepatology, 2019, 17, 1224-1227.e3.	4.4	4
28	Efficacy and safety of mammalian target of rapamycin inhibitors following intestinal and multivisceral transplantation. Clinical Transplantation, 2021, 35, e14324.	1.6	4
29	Reduced Alcohol Use Is Sustained in Patients Provided Alcohol-Related Counseling During Direct-Acting Antiviral Therapy for Hepatitis C. Digestive Diseases and Sciences, 2021, 66, 2956-2963.	2.3	3
30	Racial disparities in transjugular intrahepatic portosystemic shunt procedure outcomes. BMJ Open Gastroenterology, 2022, 9, e000747.	2.7	3
31	Burden of early hospitalization after simultaneous liver–kidney transplantation: Results from the US Multicenter SLKT Consortium. Liver Transplantation, 2022, 28, 1756-1765.	2.4	3
32	Donor–Recipient Height Mismatch Is Associated With Decreased Survival in Pediatricâ€toâ€Adult Liver Transplant Recipients. Liver Transplantation, 2021, 27, 425-433.	2.4	2
33	Identifying Ascites in Patients with Cirrhosis Using Administrative Codes and Diuretic Use: A Multicenter Study. Digestive Diseases and Sciences, 2022, 67, 4695-4701.	2.3	2
34	Radiographic and endoscopic regression of metastatic gastric cancer to the colon in the setting of 5-aminosalicylic acid use. Journal of Gastrointestinal Oncology, 2016, 6, E88-E92.	1.4	1
35	Treatment of HCV in Renal Disease: Subtle Management Considerations in the Era of Direct-Acting Antivirals. Current Hepatology Reports, 2016, 15, 285-290.	0.9	1
36	Editorial: platelet transfusions in cirrhosisâ€"do the risks outweigh the unclear benefits?. Alimentary Pharmacology and Therapeutics, 2018, 47, 1553-1554.	3.7	1

#	Article	IF	CITATIONS
37	Getting a "Grip―on Sarcopenia for the Liver Transplant Candidate: Time to Focus on Muscle Function. Liver Transplantation, 2019, 25, 1475-1476.	2.4	1
38	N-Acetylcysteine in the Management of Acute Liver Failure From Sickle Cell Hepatic Crisis. ACG Case Reports Journal, 2019, 6, e00161.	0.4	1
39	High-risk third trimester pregnancy with decompensated cirrhosis safely delivered following emergent preoperative interventional radiology for mitigation of variceal bleeding. Clinical Imaging, 2020, 68, 143-147.	1.5	1
40	Reexamining Risk Aversion: Willingness to Pursue and Utilize Nonideal Donor Livers Among US Donation Service Areas. Transplantation Direct, 2021, 7, e742.	1.6	1
41	Need for Pretransplant Midodrine Does Not Negatively Impact Simultaneous Liver-kidney Transplant Outcomes. Transplantation Direct, 2021, 7, e640.	1.6	1
42	Mechanisms of Ascites Developmentâ€"Reply. JAMA - Journal of the American Medical Association, 2016, 316, 1829.	7.4	0
43	Reply to Kim et al American Journal of Gastroenterology, 2017, 112, 807-808.	0.4	O
44	Editorial: diabetes, obesity and clinical inertiaâ€"the recipe for advanced <scp>NASH</scp> . Authors' reply. Alimentary Pharmacology and Therapeutics, 2018, 47, 1221-1222.	3.7	0
45	Reply. Gastroenterology, 2018, 154, 1546-1547.	1.3	O
46	Transjugular Intrahepatic Portosystemic Shunt for a Challenging Pregnancy. American Journal of Gastroenterology, 2020, 115, 1935-1935.	0.4	0
47	Improving the fitness of the NASH clinical trial: Standardizing the standardâ€ofâ€care intervention. Hepatology, 2022, 76, 12-14.	7.3	O